March 5, 2026 – Thermo Fisher Scientific Inc. introduced the opening of a brand new 8,000 sq. meter distribution and labeling middle to assist its immunodiagnostics enterprise in Uppsala. The brand new middle strengthens the corporate’s world provide chain for in vitro diagnostic assessments used to assist within the prognosis of allergic and autoimmune ailments and is designed to assist future development in demand from healthcare methods around the globe.

Allergic and autoimmune ailments have an effect on as many as two billion individuals worldwide, underscoring the necessity for correct, dependable and accessible diagnostic options. From its immunodiagnostic hub in Uppsala, Thermo Fisher produces diagnostic assessments that assist medical doctors in diagnosing and treating these circumstances for thousands and thousands of sufferers yearly.

The distribution and labeling middle represents an funding of $18 million (roughly SEK 160 million) in superior infrastructure, automation and operational capabilities, and enhances Thermo Fisher’s current analysis, growth and manufacturing actions in Uppsala. It enhances the corporate’s capacity to scale logistics operations, enhance effectivity and guarantee dependable supply of high-quality diagnostic merchandise to clients around the globe.

The brand new distribution and labeling middle options automated storage, scanning and labeling methods that enhance effectivity, accuracy and traceability. The middle was developed in accordance with Thermo Fisher world facility requirements and options power environment friendly design options.

Proceed studying